Somerville GLP-1 Vision Loss Law Firm

How glp-1 vision loss cases proceed under Massachusetts law

A GLP-1 vision loss claim is about one specific injury with a specific name, and getting the name right is the first thing that matters. Non-arteritic anterior ischemic optic neuropathy, almost always written NAION, is an eye stroke. Blood flow to the optic nerve head is interrupted and the nerve tissue dies. It is typically painless, it usually strikes one eye, and people very often describe noticing it on waking. The vision that is lost does not generally come back, because there is no established treatment that restores it. That is why a Somerville case turns on what the patient was told before the injury rather than on what was done after it.

The litigation has its own home. On December 15, 2025 the Judicial Panel on Multidistrict Litigation created In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163, and assigned it to Judge Karen S. Marston in the Eastern District of Pennsylvania. It began with 21 actions from three districts plus nine related tag-along cases. Eli Lilly had asked the Panel to fold the eye cases into the existing gastrointestinal MDL No. 3094; the Panel refused, holding that a separate NAION MDL would let the judge set the right level of coordination and make tracking easier, and citing its own handling of the Taxotere eye-injury litigation as precedent. A Somerville resident with a stomach or bowel injury and a Somerville resident with sudden vision loss are therefore in two different federal litigations, even though both run before the same judge.

The heart of the case is a warning gap that anyone can check in the documents. On June 6, 2025 the European Medicines Agency's safety committee concluded that NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people, and required the European product information for Ozempic, Rybelsus and Wegovy to say so, with instructions that patients report sudden vision loss without delay and that treatment stop if NAION is confirmed. The United States prescribing information tells a different story. The Ozempic label reviewed for this page runs 34 pages and warns about acute pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, severe gastrointestinal reactions, hypersensitivity, acute gallbladder disease and pulmonary aspiration under anesthesia. It does not contain the word NAION, the phrase ischemic optic neuropathy, or the phrase optic neuropathy anywhere in it. A Middlesex County patient reading the American label was not warned about the injury European regulators had already named.

Massachusetts statutes and case law

• M.G.L. c. 106 sec. 2-314. The implied warranty of merchantability, which in Massachusetts carries the function that strict product liability serves in most other states; a product that is not fit for its ordinary purpose breaches it, and a failure to warn can make an otherwise useful drug unmerchantable.
• M.G.L. c. 93A, sec. 2 and sec. 9. The consumer-protection statute; unfair or deceptive acts in trade or commerce, with double or treble damages plus attorney fees where the violation is willful or knowing and a written demand letter served 30 days before suit.
• M.G.L. c. 260 sec. 2A. The three-year limitations period for tort claims, run in these cases under the discovery rule, because a patient who is never told the drug is a suspect does not know they have a claim on the day their sight goes.
• M.G.L. c. 260 sec. 4. The separate three-year period for claims against providers, relevant when a prescriber's monitoring or informed-consent conduct is also in question rather than only the manufacturer's labeling.
• M.G.L. c. 231 sec. 85. Modified comparative negligence; recovery is reduced by the claimant's share of fault and barred above 50 per cent, which is where a manufacturer's argument about unrelated vascular risk factors gets aimed.
• M.G.L. c. 229 sec. 2. The wrongful death statute, reached in the rare case where a GLP-1 injury other than NAION, such as a bowel obstruction or aspiration event, results in death.

Common case patterns in Somerville

1. A Somerville patient on Ozempic or Wegovy for weight loss wakes with a grey or missing field in one eye, is diagnosed with NAION by a neuro-ophthalmologist, and is never told the drug is a suspect.
2. A Middlesex County patient with type 2 diabetes on Trulicity or Victoza loses vision in one eye and the loss is attributed to diabetes alone, without the GLP-1 being considered or recorded.
3. A Somerville patient stops the drug after the first eye is affected, is not warned that the second eye can follow, and suffers a second event months later.
4. A Somerville claimant whose case is really a gastrointestinal one, gastroparesis, ileus or bowel obstruction, and belongs in MDL 3094 rather than the vision MDL; the intake call sorts this before anything is filed.
5. A Somerville patient who took a compounded semaglutide from a medical spa or online seller rather than a branded pen, which changes who the defendant is and whether the MDL is the right forum at all.

Typical timeline

1. The first task is proving what the injury actually was, and that is a records job rather than an argument. NAION is diagnosed clinically by an ophthalmologist or neuro-ophthalmologist, and the file that matters usually contains a dilated exam noting optic disc swelling, visual field testing showing the characteristic altitudinal defect, and imaging used to rule out the arteritic form driven by giant cell arteritis. For a Somerville client those records sit with the treating eye practice and the hospital, and they are requested first because everything else depends on the diagnosis holding.
2. The second task is proving exposure and its timing. That means the pharmacy dispensing history, which drug, which dose, started when, and the prescribing records, and it is the step where claims most often fall apart, because people remember the pen and not the molecule. Ozempic, Wegovy and Rybelsus are semaglutide. Saxenda and Victoza are liraglutide. Trulicity is dulaglutide. Mounjaro and Zepbound are tirzepatide. The relationship between the exposure window and the date sight was lost is the spine of the case.
3. The third phase is the litigation itself, and in an MDL it does not look like an ordinary Middlesex County case. A qualifying claim is usually filed into or transferred to MDL No. 3163 in the Eastern District of Pennsylvania, where Judge Marston manages common discovery on what the manufacturers knew and when, expert work on general causation, and the selection of bellwether trials. Individual cases wait on those common rulings rather than moving independently. No global settlement has been announced and no bellwether has been tried, so any figure quoted to a Somerville client as the value of a GLP-1 eye case today is a guess.

What a Massachusetts GLP-1 vision loss claim can seek

• Past and future medical expenses, including the neuro-ophthalmology workup, imaging and any low-vision rehabilitation.
• Lost wages and, where sight loss ends a particular kind of work, lost earning capacity; this is frequently the largest element for a claimant who drove, operated equipment or read for a living.
• Pain, suffering and loss of enjoyment of life, which in a monocular vision loss case covers depth perception, night driving, reading and the loss of independence rather than physical pain.
• The cost of adaptive equipment, home modification and transportation once driving is no longer possible.
• Loss of consortium for a spouse under Massachusetts law.
• Multiple damages and attorney fees where a c. 93A violation is established as willful or knowing, which is a Massachusetts-specific layer that most states do not offer.
• Damages in a wrongful death action under c. 229 sec. 2 in the rare case where a GLP-1 injury proves fatal.

Key terms

NAION

Non-arteritic anterior ischemic optic neuropathy, an eye stroke in which blood flow to the optic nerve head is interrupted, typically painless, usually in one eye and often noticed on waking.

MDL No. 3163

The federal multidistrict litigation for GLP-1 vision loss claims, created December 15, 2025 before Judge Karen S. Marston in the Eastern District of Pennsylvania, separate from the gastrointestinal MDL No. 3094.

Failure to warn

The claim that a manufacturer knew or should have known of a risk and did not tell prescribers and patients about it, which is the core allegation in the GLP-1 eye cases.

Discovery rule

The Massachusetts principle that a limitations period can start when a claimant knew or reasonably should have known that their injury was caused by someone's conduct, rather than on the date of injury.

Bellwether trial

A representative case tried early in an MDL to show both sides how juries respond, which informs the value of the remaining claims; none has been tried in the GLP-1 vision litigation.

Implied warranty of merchantability

The M.G.L. c. 106 sec. 2-314 guarantee that a product is fit for its ordinary purpose, which does the work in Massachusetts that strict product liability does elsewhere.

Which GLP-1 litigation does your injury belong in?

More questions from Somerville residents

• Which GLP-1 drugs are involved in the Somerville vision loss cases?

  The JPML transfer order creating MDL 3163 names Ozempic, Wegovy, Saxenda and Trulicity, so the litigation is not limited to semaglutide: Saxenda is liraglutide and Trulicity is dulaglutide. The wider GLP-1 family a Somerville patient may have taken includes Ozempic, Wegovy and Rybelsus (semaglutide, Novo Nordisk), Victoza and Saxenda (liraglutide, Novo Nordisk), Trulicity (dulaglutide, Eli Lilly), Mounjaro and Zepbound (tirzepatide, Eli Lilly), and Byetta and Bydureon (exenatide, AstraZeneca). The published NAION science so far centres on semaglutide, while the filed litigation already reaches further. If you lost vision on any of them, the drug name is the first thing to establish and it is worth checking the pharmacy record rather than relying on memory.

• How much does the risk actually go up, and what does the honest number look like?

  Two credible sources give two different sizes and a Somerville reader deserves both. The Mass Eye and Ear study published in JAMA Ophthalmology on July 3, 2024, led by Dr. Joseph Rizzo in Boston, found a hazard ratio of 4.28 in patients with type 2 diabetes and 7.64 in patients who were overweight or had obesity, with 36-month cumulative incidence of 8.9 per cent against 1.8 per cent and 6.7 per cent against 0.8 per cent. Those are striking figures, and they come from a single neuro-ophthalmology referral practice with 710 and 979 patients in the two cohorts, which is exactly the setting where NAION cases concentrate. The European Medicines Agency, looking at large population studies, put it at roughly a two-fold increase, about one extra case per 10,000 person-years, and classified NAION as very rare. Both can be true, and the gap between them is the kind of thing the litigation experts will argue about.

• Does the American label warn about this?

  Not as of the label reviewed for this page. The Ozempic prescribing information runs 34 pages and carries a boxed warning about thyroid C-cell tumors plus warnings on acute pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, severe gastrointestinal reactions, hypersensitivity, acute gallbladder disease and pulmonary aspiration during general anesthesia. The words NAION, ischemic optic neuropathy and optic neuropathy do not appear anywhere in it. Europe took the other course on June 6, 2025, when the EMA's safety committee required NAION be added to the product information for Ozempic, Rybelsus and Wegovy as a very rare side effect and directed that treatment stop if NAION is confirmed. That difference between the two labels is the failure-to-warn allegation in plain view.

• How long do I have to bring a Somerville GLP-1 vision loss claim?

  Massachusetts gives three years for a tort claim under M.G.L. c. 260 sec. 2A, and in these cases the discovery rule usually decides when the three years started. A person whose sight went in 2022 and who was never told a drug might be responsible may not have had a claim to discover until the reporting began. That is an argument, not a guarantee, and it is fact-specific. The practical consequence for a Somerville reader is that an older injury is worth a phone call rather than an assumption, and a recent one should not be allowed to sit. Call Jim Glaser Law at (617) JIM-WINS.

• What should I bring to the first call about a Somerville GLP-1 eye claim?

  Four things move a case forward faster than anything else. The pharmacy printout showing which GLP-1 you took and the start and stop dates, which most pharmacies will print on request. The name of the eye doctor who diagnosed the vision loss and roughly when. Any visual field test results you were given. And a short note of what you were told about why it happened. You do not need to have any of it in hand to call. The first telephone consultation is offered without charge, and case-related costs and expenses are addressed in the written fee agreement if the firm accepts the matter.